<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90862">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02082353</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT RDCRN PIDTC-6903</org_study_id>
    <nct_id>NCT02082353</nct_id>
  </id_info>
  <brief_title>Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995</brief_title>
  <official_title>Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Primary Immune Deficiency Treatment Consortium (PIDTC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network (RDCRN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pediatric Blood and Marrow Transplant Consortium (PBMTC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic granulomatous disease (CGD) is an inherited immune system abnormality in which bone
      marrow transplantation has been shown to be curative. However the risks of transplantation
      are high and not all patients with CGD may need to undergo this high risk procedure.  This
      study will determine the long term medical condition and daily functioning of patients with
      CGD after a transplant and if possible, compare these results to patients who do not undergo
      a transplant.

      This multi-center study combines a longitudinal and cross-sectional evaluation (both retro
      and prospectively) of subjects with confirmed CGD who have already received  hematopoietic
      cell transplant (HCT) since 1995 or who will receive HCT during the study period. This study
      will investigate which subjects benefit most from HCT, and the overall outcomes in CGD
      patients with and without transplant. The study aims to identify variables contributing to
      best outcomes of HCT in subjects with CGD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control</study_design>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>HCT to date of death, up to an expected average of 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The event analyzed is death from any cause. The time from HCT to death or last follow up will be analyzed. Cause of death will also be collected. Surviving patients will be censored at the time of last observation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>an expected average of 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Engraftment will be measures in whole blood using either fluorescent in situ hybridization (FISH) for sex chromosomes or short tandem repeat PCR (STRs) in whole blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measures</measure>
    <time_frame>an expected average of 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Age appropriate testing will be performed at the cross-sectional visit in patients surviving at least two years posttransplant:
Peds QL Family Impact Module, Parent Report
Peds QL Infant Scales Module (ages 1-24 months), Parent Report
Peds QL Generic Core Scales for Toddlers (ages 2-4 yr), Parent Report
Peds QL Generic Core Scales (ages 5-25 yr), Child/Parent Reports
Peds QL Transplant Module
SF-36 (adult)
FACT BMT (adult)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>an expected average of 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>CGD or transplant-related and transplant-related infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autoimmune or inflammatory complications</measure>
    <time_frame>an expected average of 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- For HCT subjects, inflammation (inflammatory complications) includes chronic GVHD</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1480</enrollment>
  <condition>Granulomatous Disease, Chronic</condition>
  <arm_group>
    <arm_group_label>Longitudinal analysis: Retrospective CGD Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Longitudinal analysis: Prospective CGD Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-sectional Analysis: HCT CGD Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Longitudinal Analysis: Conventional Non-Transplant CGD Cohort</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood, skin swabs and/or stool samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Institutions participating in Rare Diseases Clinical Research Network (RDCRN)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant Inclusion Criteria (Part 1 - Longitudinal Analysis)

               -  CGD Patients Undergoing Transplant 1995 to Present with Birth Year In or After
                  1988

                    1. CGD Patients will be Defined by both Defective Neutrophil NADPH Oxidase
                       Function and by Clinical History Consistent with CGD

                       Patients must have BOTH of:

                       A functional assay demonstrating abnormal NADPH oxidase function (see A
                       below); AND Clinical history consistent with CGD (see B below).

                       *************************************************************************

                       Patients must have BOTH &quot;A&quot; and &quot;B&quot;:

                       A. Function: Assays of NADPH Oxidase Function

                       I. Dihydrorhodamine (DHR) Assay:

                         -  Blood sample was obtained at a time when patient was clinically stable
                            and not critically ill, with control samples performed simultaneously
                            indicating a qualified assay; and

                         -  Assay unequivocally demonstrates CGD with an SI &lt; 35 or equivalent.
                            Assay report, including mean fluorescence intensity (MFI) from
                            unstimulated and stimulated samples and gating strategy, must be
                            de-identified and provided. OR

                       II. Nitroblue Tetrazolium Oxidation Test (NBT):

                       o Diagnostic of CGD (reported as reduced granulocyte oxidative response).
                       Report must be de-identified and provided. AND

                       B. Clinical History: One or More of the Following:

                         -  Severe and/or recurrent infection (liver, perirectal or lung abscess;
                            pneumonia; adenitis; or osteomyelitis) due to, for example,
                            Staphylococcus aureus, Burkholderia sp, Serratia marcescens,
                            non-albicans Candida sp, Aspergillus sp or other mold; or Nocardia sp
                            or other deep tissue infection characteristic of CGD

                         -  Sterile granulomatous disease in respiratory, gastrointestinal or
                            urogenital tracts; or Crohn's disease-like colitis

                         -  A family history consistent with either X-linked or autosomal
                            recessive CGD

                       In cases where either functional assay (A) or history (B) is equivocal, one
                       or more of the following may be used to confirm a diagnosis of CGD:

                       C. Absent or significantly reduced in expression or abnormal size of any of
                       the 5 phox components (gp91 phox, p47 phox, p22 phox, p67phox, and p40phox)
                       of NADPH oxidase, by either:

                         -  Western blot

                         -  Northern blot OR D. Mutation in a gene encoding one of the 5 phox
                            components (gp91 phox, p47 phox, p22 phox, p67 phox, and p40 phox) of
                            NADPH oxidase that is predictive of a decreased or absent oxidative
                            burst. (Nonsense, frameshift, or previously described missense
                            mutation associated with CGD).

                       Molecular Diagnosis is Desirable In addition, molecular diagnosis (gene
                       sequencing and expression analysis) of CGD is desirable and should be
                       performed when possible.

                    2. Further Characterization of Oxidase Level, Longitudinal Study, Prospective
                       Cohort Patients who are to undergo transplantation during the study period
                       must be further characterized as oxidase-null or oxidase positive by level
                       of oxidase production by either:

                         -  DHR assay stimulation Index: where SI â‰¤ 2.5 will be classified as
                            oxidase-null CGD. Those with SI &gt; 2.5 will be classified as oxidase
                            positive CGD. A single validated test that is accepted by the PID-CGD
                            Review Panel is adequate, but testing on two occasions for validation
                            is desirable. OR

                         -  Ferricytochrome C reduction assay of granulocytes with O2 &lt; 2.3 nmoles
                            /106 cells/h classifed as oxidase-null CGD. A single validated test
                            that is accepted by the PID-CGD Review Panel is adequate, but testing
                            on two occasions for validation is desirable.

                       OR

                       o Genetic sequencing reporting a mutation that is unequivocally associated
                       to absent oxidase production. (e.g. null mutations) will be classified as
                       oxidase-null CGD (See discussion in Appendix I for how family history,
                       genotype and CGD mutation information will be applied to assigning patients
                       lacking any quantitative oxidase activity measurements to residual
                       oxidase-null or residual oxidase-positive groups).

                    3. Longitudinal Study, Retrospective Cohort Patients who have already been
                       transplanted will be included regardless of whether further
                       characterization by oxidase level (or genotype/mutation data) is possible
                       or not.

               -  Non-Transplanted CGD Patients with Birth Year In or After 1988 A non-transplant
                  (conventional therapy) group of GGD subjects will be enrolled in the
                  longitudinal study. The non-transplant subjects will be selected from the
                  potentially eligible (retrospective) patient cohort with diagnosis of CGD
                  treated with conventional non-transplant therapy. Participating sites will enter
                  their entire retrospective cohort of CGD patients having birth year in or after
                  1988 into the registration cohort for this protocol. Baseline for both
                  non-transplant subjects and HCT subjects for the purpose of comparing survival
                  will be the year of birth. However, for non-transplant subjects, many of the
                  detailed analyses such as infection and autoimmune complication rates will be
                  assessed in the year preceding the date of last contact.

          -  Participant Inclusion Criteria (Part 2 - Cross-Sectional Analysis) To participate in
             the Cross-Sectional Analysis, patients must have previously been enrolled into the
             Longitudinal Analysis of Protocol 6903. All transplanted subjects in the
             Cross-Sectional Analysis are surviving and shall have at least 3 years of follow-up
             post-transplant to be included. Non-transplanted CGD subjects will become eligible
             for consideration for the Cross-Sectional Analysis if they were eligible and enrolled
             in the retrospective cohort of the Longitudinal Analysis, and if/when they are &gt; 3
             years post-diagnosis of CGD. Provision of written informed consent will be required
             for inclusion in the Cross-Sectional Analysis.

        Exclusion Criteria:

          -  Participant Exclusion Criteria (Longitudinal and Cross- Sectional Analyses)

               -  Presence of other primary immunodeficiency syndromes that do not meet the
                  clinical and laboratory criteria for CGD.

               -  Rac2 Deficiency

               -  MPO Deficiency

               -  Glutathione deficiency

               -  Leukocyte adhesion deficiency syndrome

          -  Non-transplant subjects:

               -  The above exclusions pertain.

               -  In addition, non-transplant subjects will be excluded if the only assessment of
                  oxidase function available is the nitroblue tetrazolium (NBT) test (a
                  non-quantitative test).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth M. Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry L Malech, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi D Notarangelo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Neena Kapoor, MD</last_name>
      <phone>323-361-2546</phone>
      <email>nkapoor@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Neena Kapoor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ted Moore, MD</last_name>
      <phone>310-825-6708</phone>
      <email>tbmoore@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Ted Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-1278</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mort Cowan</last_name>
      <phone>415-476-2188</phone>
      <email>mcowan@peds.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Mort Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital/ Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Porteus, MD</last_name>
      <phone>650-725-6520</phone>
      <email>mporteus@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Porteus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center, Washington DC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brett Loechelt, MD</last_name>
      <phone>202-476-2805</phone>
      <email>bloechel@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Brett Loechelt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital, St. Petersburg FL</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aleksandra Petrovic, MD</last_name>
      <phone>727-767-6856</phone>
      <email>Aleksandra.Petrovic@allkids.org</email>
    </contact>
    <investigator>
      <last_name>Aleksandra Petrovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/ Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Stenger, MD</last_name>
      <phone>404-785-1272</phone>
      <email>Elizabeth.Stenger@choa.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Stenger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New Orleans at LSUHSC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lolie Yu, MD</last_name>
      <phone>504-896-9740</phone>
      <email>lyu@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Lolie Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center Genetic Immunotherapy Section</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Kang, MD</last_name>
      <phone>301-402-7567</phone>
      <email>ekang@niaid.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sung-Yun Pai, MD</last_name>
      <phone>617-919-2508</phone>
      <email>sung-yun.pai@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sung-Yun Pai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Connelly, MD</last_name>
      <phone>737-936-4000</phone>
      <email>jaconnel@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>James Connelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Hospital/ St. Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alan Knutsen, MD</last_name>
      <phone>314-577-5638</phone>
      <email>knutsenm@slu.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Knutsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University/ St.Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shalini Shenoy, MD</last_name>
      <phone>314-454-6018</phone>
      <email>Shenoy@kids.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Shalini Shenoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfred Gillio, MD</last_name>
      <phone>201-996-5645</phone>
      <email>agillio@humed.com</email>
    </contact>
    <investigator>
      <last_name>Alfred Gillio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Farid Boulad, MD</last_name>
      <phone>212-639-6684</phone>
      <email>bouladf@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Farid Boulad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suhag Parikh, MD</last_name>
      <phone>919-668-1100</phone>
      <email>suhag.parikh@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Suhag Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra Filipovich, MD</last_name>
      <phone>513-636-5917</phone>
      <email>Lisa.Filipovich@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Alexandra Filipovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evan Shereck, MD</last_name>
      <phone>503-494-0829</phone>
      <email>Shereck@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Evan Shereck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen Sullivan, MD, PhD</last_name>
      <phone>215-590-1697</phone>
      <email>sullivak@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Sullivan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victor Aquino, MD</last_name>
      <phone>214-648-8800</phone>
      <email>victor.aquino@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Aquino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Texas Children's Hosp. CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Shearer, MD</last_name>
      <phone>832-824-1274</phone>
      <email>wtsheare@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>William Shearer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas/Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Troy Quigg, MD</last_name>
      <phone>210-575-7348</phone>
      <email>Troy.Quigg@MHShealth.com</email>
    </contact>
    <investigator>
      <last_name>Troy Quigg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center/ University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Pulsipher</last_name>
      <phone>801-662-4830</phone>
      <email>Michael.pulsipher@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Pulsipher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauri M Burroughs, MD</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Lauri M Burroughs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin/ American Family Children's Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705-2275</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenneth DeSantes, MD</last_name>
      <phone>608-263-8563</phone>
      <email>kbdesantes@pediatrics.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth DeSantes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-4874</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Thakar, MD</last_name>
      <phone>414-266-6840</phone>
      <email>mthakar@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Monica Thakar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeff Davis, MD</last_name>
      <phone>604-875-3577</phone>
      <email>jdavis@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Jeff Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geoff Cuvelier, MD</last_name>
      <phone>204-787-8689</phone>
      <email>geoff.cuvelier@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Geoff Cuvelier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU St. Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elie Haddad, MD</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>6217</phone_ext>
      <email>elie.haddad@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Elie Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.niaid.nih.gov/Pages/default.aspx</url>
    <description>The National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Granulomatous Disease, Chronic</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Granulomatous Disease, Chronic</mesh_term>
    <mesh_term>Granuloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
